Biotherapeutic Technology Companies

AngioChem is a clinical-stage biotechnology company discovering and developing breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. The company’s proprietary platform for Engineered Peptide Compounds (EPiC) offers a completely new, innovative way to develop drugs to cross the blood-brain barrier and positions AngioChem as a leader in this field. Based on the EPiC platform, AngioChem has created a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases and related disorders, including brain cancer, cancer metastases, neurodegenerative and metabolic diseases.

Bioniche Life Scieces is a research-based, technology-driven Canadian biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. Discovery research at Bioniche focuses primarily on areas of medicine where there is a strong need for safer, more efficacious therapies: specifically in oncology and immunomodulation. Pre-clinical research and formulation research is conducted in the company's facilities located within the Bioniche Therapeutics Research Centre at the NRC Biotechnology Research Institute in Montreal, Quebec.

Ico Therapeutics, Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo Therapeutics is a “Search and Development” company. By focusing efforts on development instead of research, iCo’s business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development by iCo of these therapeutics may include drug delivery technologies—such as sustained release, biodegradable matrices, etc to extend patent coverage.

ImmunoVaccine Technologies, Inc. is a clinical stage biotechnology company developing high potential vaccines for human health. IVT’s unique patented vaccine delivery and enhancement technology, the DepoVax™ platform, has achieved exciting results and positive pre-clinical safety data. IVT’s technology has attracted multiple partnerships and generated revenues through two licenses of its technology to Pfizer Animal Health.

Stem Cell Therapeutics Corp. is a Canadian public biotechnology company focused on the development and commercialization of drug-based therapies to treat cental nervous system diseases and the therapeutics that control adult stem cells in the body.

Tekmira Pharmaceuticals Corporation is an emerging leader in the advancement of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.